These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11078496)

  • 1. In vivo cytoreduction studies and cell sorting--enhanced tumor-cell detection in high-risk neuroblastoma patients: implications for leukapheresis strategies.
    Faulkner LB; Garaventa A; Paoli A; Tintori V; Tamburini A; Lacitignola L; Veltroni M; Lo Piccolo MS; Viscardi E; Milanaccio C; Tondo A; Spinelli S; Bernini G; De Bernardi B
    J Clin Oncol; 2000 Nov; 18(22):3829-36. PubMed ID: 11078496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purging of tumor cells from leukapheresis products: experimental and clinical aspects.
    Kvalheim G; Wang MY; Pharo A; Holte H; Jacobsen E; Beiske K; Kvaløy S; Smeland E; Funderud S; Fodstad O
    J Hematother; 1996 Aug; 5(4):427-36. PubMed ID: 8877718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
    Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
    J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation.
    Saarinen UM; Wikström S; Mäkipernaa A; Lanning M; Perkkiö M; Hovi L; Rapola J; Sariola H
    J Clin Oncol; 1996 Oct; 14(10):2791-802. PubMed ID: 8874341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
    Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
    Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
    Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
    Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.
    Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M
    Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of breast cancer cell detection by immunomagnetic enrichment.
    Krüger W; Tögel F; Rössing S; Kröger N; Zander AR
    Cytotherapy; 1999; 1(2):135-9. PubMed ID: 19746590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection.
    Tchirkov A; Kanold J; Giollant M; Halle-Haus P; Berger M; Rapatel C; Lutz P; Bergeron C; Plantaz D; Vannier JP; Stephan JL; Favrot M; Bordigoni P; Malet P; Briançon G; Deméocq F
    Med Pediatr Oncol; 1998 Apr; 30(4):228-32. PubMed ID: 9473757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
    Wagner LM; Guichard SM; Burger RA; Morton CL; Straign CM; Ashmun RA; Harris LC; Houghton PJ; Potter PM; Danks MK
    Cancer Res; 2002 Sep; 62(17):5001-7. PubMed ID: 12208753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma.
    Handgretinger R; Greil J; Schürmann U; Lang P; Gonzalez-Ramella O; Schmidt I; Führer R; Niethammer D; Klingebiel T
    J Hematother; 1997 Jun; 6(3):235-42. PubMed ID: 9234178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma.
    Choi YB; Bae GE; Lee NH; Kim JS; Lee SH; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2015 Aug; 30(8):1062-7. PubMed ID: 26240483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
    Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
    J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model system for the enrichment of tumor cells from peripheral blood and bone marrow using immunomagnetic ferrofluids.
    Kemshead JT; Hancock JP; Liberti PA
    Prog Clin Biol Res; 1994; 389():593-600. PubMed ID: 7700925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.